GLP1R and diabetes mellitus: In our cohort, the prescription of GLP-1 RAs and SGLT2is reflects a growing preference for agents with established cardiorenal benefits in other populations with diabetes, over older antidiabetic drugs, which may lack protective effects and pose risks of significant side effects—especially in this clinically complex and historically underrepresented population.